drugset / Trial / NCT07246889
Study of AHB-137 in Participants With Chronic Hepatitis B (CHB) Treated With Nucleos(t)Ide Analogues (NAs)(AUSHINE)
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This study is a randomized, double-blind, multicenter phase 3 clinical trial to evaluate the efficacy and safety of AHB-137 injection in participants with HBeAg-negative CHB treated with NAs.
Timeline
- Start
- 2025-08-12
- Primary completion
- 2026-12-18
- Completion
- 2027-10-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AHB-137 | Antisense oligonucleotide | — | Subcutaneous |